About Zacharon Pharmaceuticals
Zacharon Pharmaceuticals is a company based in San Diego (United States) founded in 2004 was acquired by BioMarin Pharmaceutical in January 2013. Zacharon Pharmaceuticals has raised $4.05 million across 11 funding rounds from investors including BioMarin Pharmaceutical, NIH and HHS. Zacharon Pharmaceuticals offers products and services including Glycan-Targeted Drugs, Drug Development Platform, and Sensi-Pro Assay. Zacharon Pharmaceuticals operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Zacharon Pharmaceuticals, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.05 M (USD)
in 11 rounds
-
Latest Funding Round
$33 K (USD), Series A
Mar 30, 2012
-
Investors
BioMarin Pharmaceutical
& 3 more
-
Employee Count
Not available
-
Acquired by
BioMarin Pharmaceutical
(Jan 07, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Zacharon Pharmaceuticals
Zacharon Pharmaceuticals offers a comprehensive portfolio of products and services, including Glycan-Targeted Drugs, Drug Development Platform, and Sensi-Pro Assay.
Small molecule drugs for treating lysosomal storage diseases and cancer.
Platform for discovering glycan-targeted treatments via screening.
Assay for detecting lysosomal storage diseases through partnerships.
Funding Insights of Zacharon Pharmaceuticals
Zacharon Pharmaceuticals has successfully raised a total of $4.05M across 11 strategic funding rounds. The most recent funding activity was a Series A round of $33 thousand completed in March 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Zacharon Pharmaceuticals
Zacharon Pharmaceuticals has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include BioMarin Pharmaceutical, NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Zacharon Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Zacharon Pharmaceuticals
Investment portfolio details for Zacharon Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Zacharon Pharmaceuticals
Detailed financials for Zacharon Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zacharon Pharmaceuticals Comparisons
Peer comparison for Zacharon Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Zacharon Pharmaceuticals
Zacharon Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
Detailed competitors of Zacharon Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zacharon Pharmaceuticals
Complete news archive for Zacharon Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zacharon Pharmaceuticals
Zacharon Pharmaceuticals was founded in 2004 and raised its 1st funding round 4 years after it was founded.
Zacharon Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Robin M Jackman is the current CEO of Zacharon Pharmaceuticals.
Zacharon Pharmaceuticals is a funded company, having raised a total of $4.05M across 11 funding rounds to date.
Zacharon Pharmaceuticals was founded in 2004 in San Diego, United States, within the biotechnology sector. Small molecule therapeutics were developed to target glycan biosynthesis, supported by a platform integrating cell-based screening and glycan structural analysis for drug discovery. Programs addressed heparan sulfate inhibitors for mucopolysaccharidosis III and ganglioside inhibitors for Tay-Sachs and Sandhoff diseases. Acquisition by BioMarin occurred in January 2013 for 10 million.
Zacharon Pharmaceuticals's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Zacharon Pharmaceuticals offers Glycan-Targeted Drugs, Drug Development Platform, and Sensi-Pro Assay.
Zacharon Pharmaceuticals has 4 investors. Key investors include BioMarin Pharmaceutical, NIH, HHS, and Avalon Bio Ventures.